Imunon | 10-Q: Quarterly report
Imunon GAAP EPS of -$0.52 Beats by $0.05
Imunon 1Q Loss/Shr 52c >IMNN
Imunon 1Q Loss/Shr 52c >IMNN
Imunon 1Q Research and Development Expenses $3.3M >IMNN
Imunon 1Q Research and Development Expenses $3.3M >IMNN
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on develo
IMUNON Appoints Stacy R. Lindborg As President And CEO, Effective May 13, 2024
Assumes leadership role as Company anticipates multiple near-term clinical milestonesBrings extensive leadership and experience in drug development and business strategyLAWRENCEVILLE, N.J., May 08, 20
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
PDF Version Assumes leadership role as Company anticipates multiple near-term clinical milestonesBrings extensive leadership and experience in drug development and business strategyLAWRENCEVILLE,
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
PDF Version LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and nex
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
By Chris Wack Imunon shares rose after the company received clearance from the U.S. Food and Drug Administration to begin a Phase 1 clinical trial with a seasonal Covid-19 booster vaccine. Shares we
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101
PDF Version Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarterLAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IM
IMUNON Reports Compliance With Nasdaq Listing Requirements
PDF Version LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on developing DNA-
Imunon Withdraws Filing for Securities Offering
Imunon Withdraws Filing for Securities Offering
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
Imunon Is Maintained at Buy by HC Wainwright & Co.
Imunon Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Imunon, Raises Price Target to $13
HC Wainwright & Co. analyst Emily Bodnar maintains Imunon (NASDAQ:IMNN) with a Buy and raises the price target from $12 to $13.
Imunon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 692.68% HC Wainwright & Co. $12 → $13 Maintains Buy 03/13/2024 631.71% HC Wainwright & Co. → $1
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)
Top Midday Gainers
Avalo Therapeutics (AVTX) shares skyrocketed amid heavy trading Thursday after the company completed the acquisition of privately held AlmataBio and said late Wednesday it entered into a private place
Earnings Call Summary | Imunon(IMNN.US) Q4 2023 Earnings Conference
The following is a summary of the Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript:Financial Performance:Imunon ended 2023 with $15.7 million in cash and investments.The company used $18.9 million
No Data